• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Imatinib plasma levels: correlation with clinical benefit in GIST patients.

作者信息

Widmer N, Decosterd L A, Csajka C, Montemurro M, Haouala A, Leyvraz S, Buclin T

出版信息

Br J Cancer. 2010 Mar 30;102(7):1198-9. doi: 10.1038/sj.bjc.6605584. Epub 2010 Feb 23.

DOI:10.1038/sj.bjc.6605584
PMID:20179709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2853086/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c551/2853086/35c490a42bf3/6605584f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c551/2853086/35c490a42bf3/6605584f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c551/2853086/35c490a42bf3/6605584f1.jpg

相似文献

1
Imatinib plasma levels: correlation with clinical benefit in GIST patients.伊马替尼血药浓度：与胃肠间质瘤患者临床获益的相关性
Br J Cancer. 2010 Mar 30;102(7):1198-9. doi: 10.1038/sj.bjc.6605584. Epub 2010 Feb 23.
2
The role of imatinib plasma level testing in gastrointestinal stromal tumor.伊马替尼血浆水平检测在胃肠道间质瘤中的作用。
Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S45-50. doi: 10.1007/s00280-010-1527-2. Epub 2010 Dec 8.
3
Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.ABCG2基因多态性与伊马替尼治疗胃肠道间质瘤患者临床疗效的相关性
Cancer Chemother Pharmacol. 2015 Jan;75(1):173-82. doi: 10.1007/s00280-014-2630-6. Epub 2014 Nov 23.
4
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.胃肠道间质瘤患者药代动力学研究的价值
Future Oncol. 2013 Nov;9(11):1675-7. doi: 10.2217/fon.13.126. Epub 2013 Jul 17.
5
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.伊马替尼的血浆水平与不可切除/转移性胃肠道间质瘤患者的临床获益相关。
J Clin Oncol. 2009 Jul 1;27(19):3141-7. doi: 10.1200/JCO.2008.20.4818. Epub 2009 May 18.
6
The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.伊马替尼治疗药物监测在慢性髓性白血病和转移性或不可切除胃肠道间质瘤患者中的作用。
Ther Drug Monit. 2012 Feb;34(1):85-97. doi: 10.1097/FTD.0b013e31823cdec9.
7
Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.伊马替尼血药浓度监测指导下剂量调整用于胃肠间质瘤患者伊马替尼相关毒性管理。
J Korean Med Sci. 2013 Aug;28(8):1248-52. doi: 10.3346/jkms.2013.28.8.1248. Epub 2013 Jul 31.
8
Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.晚期胃肠间质瘤患者伊马替尼血药谷浓度的横断面研究：胃肠切除术对伊马替尼暴露的影响。
J Clin Oncol. 2010 Mar 20;28(9):1554-9. doi: 10.1200/JCO.2009.26.5785. Epub 2010 Feb 22.
9
Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels.胃肠道间质瘤的个体化癌症治疗：肿瘤基因分型与伊马替尼血药浓度的协同作用。
Curr Opin Oncol. 2010 Jul;22(4):336-41. doi: 10.1097/CCO.0b013e32833a6b8e.
10
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.甲磺酸伊马替尼及其代谢物在儿童和青年中的群体药代动力学。
Cancer Chemother Pharmacol. 2009 Jan;63(2):229-38. doi: 10.1007/s00280-008-0730-x. Epub 2008 Apr 9.

引用本文的文献

1
Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib.基于生理学的 SARS-CoV-2 感染患者药代动力学建模方法：以伊马替尼为例的病例研究。
J Clin Pharmacol. 2022 Oct;62(10):1285-1296. doi: 10.1002/jcph.2065. Epub 2022 May 8.
2
Precision Dosing of Targeted Therapies Is Ready for Prime Time.精准靶向治疗的剂量调整已准备好进入黄金时代。
Clin Cancer Res. 2021 Dec 15;27(24):6644-6652. doi: 10.1158/1078-0432.CCR-20-4555. Epub 2021 Sep 21.
3
Tailored management of primary gastrointestinal stromal tumors.

本文引用的文献

1
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.采用液相色谱串联质谱法对新型靶向抗癌药物伊马替尼、尼洛替尼、达沙替尼、舒尼替尼、索拉非尼和拉帕替尼进行治疗药物监测。
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96. doi: 10.1016/j.jchromb.2009.04.045. Epub 2009 May 13.
2
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.伊马替尼的血浆水平与不可切除/转移性胃肠道间质瘤患者的临床获益相关。
J Clin Oncol. 2009 Jul 1;27(19):3141-7. doi: 10.1200/JCO.2008.20.4818. Epub 2009 May 18.
3
原发性胃肠道间质瘤的个体化治疗。
Cancer. 2019 Jul 1;125(13):2164-2171. doi: 10.1002/cncr.32067. Epub 2019 Apr 1.
4
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.肿瘤学中激酶抑制剂治疗药物监测的实用建议
Clin Pharmacol Ther. 2017 Nov;102(5):765-776. doi: 10.1002/cpt.787. Epub 2017 Sep 7.
5
Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.伊马替尼在一大组胃肠道间质瘤患者观察队列中的药代动力学
Clin Pharmacokinet. 2017 Mar;56(3):287-292. doi: 10.1007/s40262-016-0439-7.
6
How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.癌症中酪氨酸激酶抑制剂的“最佳”采样时间有多“最佳”？实际考量
Clin Pharmacokinet. 2016 Oct;55(10):1171-1177. doi: 10.1007/s40262-016-0394-3.
7
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.抗癌酪氨酸激酶抑制剂治疗药物监测实用指南：聚焦药代动力学靶点
Clin Pharmacokinet. 2014 Apr;53(4):305-25. doi: 10.1007/s40262-014-0137-2.
8
Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?对于晚期肝细胞癌患者，在患者体内重新增加索拉非尼剂量是否安全且可耐受？
Int J Clin Oncol. 2014 Dec;19(6):1029-36. doi: 10.1007/s10147-014-0668-4. Epub 2014 Feb 13.
9
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.伊马替尼耐药的晚期胃肠道间质瘤的现行和新兴治疗策略。
Ther Adv Med Oncol. 2012 Sep;4(5):255-70. doi: 10.1177/1758834012450935.
10
Contribution of tumoral and host solute carriers to clinical drug response.肿瘤和宿主溶质载体对临床药物反应的贡献。
Drug Resist Updat. 2012 Feb-Apr;15(1-2):5-20. doi: 10.1016/j.drup.2012.01.009. Epub 2012 Mar 28.
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
无伊马替尼血浆水平与目标基因型与疗效和耐受性的关系。
Br J Cancer. 2008 May 20;98(10):1633-40. doi: 10.1038/sj.bjc.6604355. Epub 2008 May 6.
4
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.伊马替尼在慢性期慢性髓性白血病中的药代动力学及其与疗效和安全性的相关性：IRIS研究的亚组分析
Blood. 2008 Apr 15;111(8):4022-8. doi: 10.1182/blood-2007-10-116475. Epub 2008 Feb 6.
5
Therapeutic drug monitoring in CML patients on imatinib.伊马替尼治疗的慢性粒细胞白血病患者的治疗药物监测
Blood. 2007 Sep 1;110(5):1699-701; author reply 1701. doi: 10.1182/blood-2007-03-079871.
6
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.在慢性髓性白血病中，伊马替尼的谷浓度血浆水平与对标准剂量伊马替尼的细胞遗传学和分子反应均相关。
Blood. 2007 Apr 15;109(8):3496-9. doi: 10.1182/blood-2006-07-036012. Epub 2006 Dec 27.
7
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.伊马替尼及其主要代谢产物在晚期胃肠道间质瘤患者中的药代动力学-药效学关系。
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6073-8. doi: 10.1158/1078-0432.CCR-05-2596.
8
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.伊马替尼的群体药代动力学及α-酸性糖蛋白的作用。
Br J Clin Pharmacol. 2006 Jul;62(1):97-112. doi: 10.1111/j.1365-2125.2006.02719.x.
9
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.伊马替尼在胃肠道间质瘤患者中的药代动力学：一项随时间推移的回顾性群体药代动力学研究。欧洲癌症研究与治疗组织软组织和骨肉瘤组
Cancer Chemother Pharmacol. 2005 Apr;55(4):379-386. doi: 10.1007/s00280-004-0876-0. Epub 2004 Dec 9.
10
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.转移性胃肠道间质瘤患者的激酶突变与伊马替尼反应
J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190.